|
|
News Breaks | | | | October 23, 2012 | | 08:00 EDT |  | REGN | Regeneron survey shows higher Eylea use already, says RW Baird
Baird said new survey data shows a surprising level of Eylea use already and significant projected near term growth giving confidence the drug can beat/raise through the next several quarters. Shares are Outperform rated with a $175 price target. | |
|
News For REGN From The Last 14 Days Check below for free stories on REGN the last two weeks. |
|
|
| June 18, 2013 | | 11:52 EDT |  | REGN | Stocks with call strike movement; REGN MU
 Subscribe for More Information | | | 08:36 EDT | | REGN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. | | | June 6, 2013 | | 05:49 EDT |  | REGN | Regeneron, Bayer reports positive Phase 3 results for Eylea
Regeneron Pharmaceuticals (REGN) and Bayer HealthCare (BAYRY) announced positive top-line results for EYLEA Injection from the Phase 3 MYRROR study in myopic choroidal neovascularization. In this trial, patients receiving EYLEA at an initial dose of 2 milligrams, followed by treatment on an as-needed basis, had a mean improvement in best-corrected visual acuity from baseline at week 24 of 12.1 letters, compared to a loss of 2.0 letters in patients receiving sham injections. The most common adverse events observed in the MYRROR trial that occurred with a frequency of 2% or more were conjunctival hemorrhage, dry eye, eye pain, headache and nasopharyngitis. | |
|
|
|
|
|
|
